NASDAQ:LMAT LeMaitre Vascular (LMAT) Stock Price, News & Analysis $80.69 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$81.76 +1.08 (+1.33%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About LeMaitre Vascular Stock (NASDAQ:LMAT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LeMaitre Vascular alerts:Sign Up Key Stats Today's Range$79.58▼$81.0250-Day Range$78.80▼$105.7852-Week Range$78.22▼$118.01Volume126,706 shsAverage Volume263,315 shsMarket Capitalization$1.85 billionP/E Ratio28.31Dividend Yield1.24%Price Target$110.60Consensus RatingHold Company Overview LeMaitre Vascular, Inc. is a medical device company that develops, manufactures and markets products used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on blood vessels outside the heart and brain, including procedures involving the carotid, lower-extremity and aortic vascular systems. The company’s product portfolio includes biologic and synthetic vascular grafts, angioplasty and thrombectomy catheters, valvulotomes, carotid shunts, vascular clamps and other devices used in open and minimally invasive vascular surgery. LeMaitre also offers products intended to support vessel repair, bypass procedures and the management of vascular access and blood flow during surgery. Headquartered in Burlington, Massachusetts, LeMaitre Vascular serves hospitals and healthcare providers in the United States and international markets through a combination of direct sales organizations and distributors. The company was founded in 1983 by George W. LeMaitre, who continues to serve as its chief executive officer.AI Generated. May Contain Errors. Read More LeMaitre Vascular Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreLMAT MarketRank™: LeMaitre Vascular scored higher than 87% of companies evaluated by MarketBeat, and ranked 62nd out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingLeMaitre Vascular has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 4 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialLeMaitre Vascular has a consensus price target of $110.60, representing about 37.1% upside from its current price of $80.69.Amount of Analyst CoverageLeMaitre Vascular has only been the subject of 4 research reports in the past 90 days.Read more about LeMaitre Vascular's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.03% Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 10.03% in the coming year, from $2.89 to $3.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 28.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.05.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 28.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.59.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LeMaitre Vascular's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.21% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 6.87.Change versus previous monthShort interest in LeMaitre Vascular has recently increased by 2.71%, indicating that investor sentiment is decreasing. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldLeMaitre Vascular pays a meaningful dividend of 1.24%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 35.09%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 31.45% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.Read more about LeMaitre Vascular's dividend. News and Social Media1.6 / 5News SentimentN/A News SentimentLeMaitre Vascular has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for LeMaitre Vascular this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have not sold or bought any company stock.Percentage Held by Insiders7.40% of the stock of LeMaitre Vascular is held by insiders.Percentage Held by Institutions84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LeMaitre Vascular's insider trading history. Receive LMAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LMAT Stock News HeadlinesGE HealthCare Technologies (NASDAQ:GEHC) & LeMaitre Vascular (NASDAQ:LMAT) Head to Head ComparisonOctober 4, 2026 | americanbankingnews.comBarrington Sticks to Its Buy Rating for Lemaitre Vascular (LMAT)October 3, 2026 | theglobeandmail.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition MachineOctober 1, 2026 | seekingalpha.comIs LeMaitre Vascular (LMAT) A Bargain Following Its 90 Day Pullback?September 25, 2026 | finance.yahoo.comLeMaitre Vascular (LMAT) Stock Looks Fully Priced On Its 57% Five Year RunSeptember 24, 2026 | finance.yahoo.comLeMaitre Vascular Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Customer Data Is ExposedSeptember 23, 2026 | prnewswire.com2 profitable stocks to target this week and 1 we ignoreSeptember 21, 2026 | msn.comSee More Headlines LMAT Stock Analysis - Frequently Asked Questions How have LMAT shares performed this year? LeMaitre Vascular's stock was trading at $81.10 at the start of the year. Since then, LMAT stock has decreased by 0.5% and is now trading at $80.69. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular, Inc. (NASDAQ:LMAT) issued its quarterly earnings results on Tuesday, August, 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.81 by $0.07. LeMaitre Vascular's revenue was up 9.6% compared to the same quarter last year. Read the conference call transcript. Does LeMaitre Vascular have any subsidiaries? The following companies are subsidiaries of LeMaitre Vascular: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and more. Who are LeMaitre Vascular's major shareholders? LeMaitre Vascular's top institutional investors include Congress Asset Management Co. (4.20%) and GAMMA Investing LLC. Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Lawrence J Jasinski, Bridget A Ross, Trent G Kamke and John A Roush. View institutional ownership trends. How do I buy shares of LeMaitre Vascular? Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/04/2026Record date for 9/3 Dividend8/20/2026Ex-Dividend for 9/3 Dividend8/20/2026Dividend Payable9/03/2026Today10/11/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LMAT's financial health is in the Red zone, according to TradeSmith. LMAT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:LMAT CIK1158895 Webwww.lemaitre.com Phone(781) 221-2266Fax781-425-5049Employees655Year Founded1983Price Target and Rating Average Price Target for LeMaitre Vascular$110.60 High Price Target$127.00 Low Price Target$94.00 Potential Upside/Downside+37.1%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.85 Trailing P/E Ratio28.31 Forward P/E Ratio27.92 P/E Growth2.33Net Income$57.73 million Net Margins25.02% Pretax Margin32.29% Return on Equity15.63% Return on Assets10.06% Debt Debt-to-Equity Ratio0.40 Current Ratio16.31 Quick Ratio13.96 Sales & Book Value Annual Sales$249.60 million Price / Sales7.39 Cash Flow$2.90 per share Price / Cash Flow27.80 Book Value$17.35 per share Price / Book4.65Miscellaneous Outstanding Shares22,870,000Free Float21,177,000Market Cap$1.85 billion OptionableOptionable Beta0.48 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LMAT) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredFive Seats Could Shift Washington’s DirectionDemocrats need just five more seats to flip House control, with forecasts giving them a 61% to 85% chance ahea...USA Capital Gold | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
